Reading this on a mobile device? Try our optimized mobile version here:

November 29, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
  Health Care & Policy 
  • J&J's tuberculosis drug gets FDA panel support
    An FDA panel has backed the safety and efficacy of Johnson & Johnson's bedaquiline drug for tuberculosis, but also pointed out possible heart and liver-safety issues. The drug works by targeting the adenosine triphosphate synthase enzyme, which the pathogen requires to generate energy. Reuters (11/28) LinkedInFacebookTwitterEmail this Story
  • AesRx reports promising data for sickle cell disease drug
    AesRx said data from a Phase I study of its sickle cell disease treatment Aes-103 showed the drug is safe and well-tolerated by patients. The data are set to be presented at a hematology meeting. Following the positive findings, AesRx has started a second trial at the NIH Clinical Center in Bethesda, Md., that will involve patients with sickle cell disease. Mass High Tech (Boston) (11/27) LinkedInFacebookTwitterEmail this Story
  • Method allows aging stem cells to rejuvenate
    Canadian researchers have developed a method to prompt aging stem cells to rejuvenate. The researchers created a "micro-environment" conducive to growing heart tissue from stem cells collected from elderly patients. The discovery could allow for the development of "young" patches for treating or healing damaged or diseased hearts without the fear of rejection. (India)/Indo-Asian News Service (11/28) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Panacela lands $4.6M contract to develop infectious disease drugs
    The Ministry of Industry and Trade of the Russian Federation awarded Panacela Labs a contract worth around $4.6 million to develop Xenomycins, a family of anti-infective compounds that works by targeting pathogenic microbe DNA. In preclinical studies, Xenomycins showed efficacy against parasites and pathogenic fungi that cause candidiasis, aspergillosis and other infections. "We expect that the contract will enable us to accelerate our preclinical program and evaluate the potential application of Xenomycins against life threatening infectious diseases," Panacela CEO Dmitry Tyomkin said. Genetic Engineering & Biotechnology News (11/27) LinkedInFacebookTwitterEmail this Story
  Industry Deals 
  Food & Agriculture 
  • Study linking biotech corn to cancer has serious defects, EFSA says
    There is no need to re-assess the safety of Monsanto's biotech corn NK603 because the study that linked the crop to cancer risks in rats had major design and methodology flaws, according to the European Food Safety Authority. "Conclusions cannot be regarded as scientifically sound because of inadequacies in the design, reporting and analysis of the study as outlined in the paper," EFSA said. The Wall Street Journal (11/28) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Poll: Advanced biofuel execs believe federal support will stay
    Most of the participants in last month's Advanced Biofuels Markets conference in San Francisco were optimistic that federal support for biofuels would be continued or increased in 2013, and that commercial-scale cellulosic ethanol production would be achieved next year, a survey showed. More than 67% of respondents believed that the Renewable Fuel Standard would stay in its current form through 2013, the poll showed. (11/28) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

We acquire the strength we have overcome."
--Ralph Waldo Emerson,
American writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information